論文

査読有り 国際誌
2017年9月

A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.

Hematological oncology
  • Takuro Matsumoto
  • ,
  • Takeshi Hara
  • ,
  • Yuhei Shibata
  • ,
  • Nobuhiko Nakamura
  • ,
  • Hiroshi Nakamura
  • ,
  • Soranobu Ninomiya
  • ,
  • Junichi Kitagawa
  • ,
  • Nobuhiro Kanemura
  • ,
  • Naoe Goto
  • ,
  • Yusuke Kito
  • ,
  • Senji Kasahara
  • ,
  • Toshiki Yamada
  • ,
  • Michio Sawada
  • ,
  • Tatsuhiko Miyazaki
  • ,
  • Tsuyoshi Takami
  • ,
  • Tamotsu Takeuchi
  • ,
  • Hisataka Moriwaki
  • ,
  • Hisashi Tsurumi

35
3
開始ページ
288
終了ページ
295
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1002/hon.2285
出版者・発行元
WILEY

We have reported the efficacy of the salvage chemotherapy P-IMVP16/CBDCA for patients with diffuse large B cell lymphoma (DLBCL) who had previously received CHOP before the availability of rituximab (R). Here, we confirmed the efficacy of R combined with P-IMVP16/CBDCA as a salvage chemotherapy for patients with DLBCL, who had previously received R-CHOP. We retrospectively analysed 59 patients with relapse or refractory DLBCL (38 male patients and 21 female patients) presenting between June 2004 and June 2013. The patients received R 375 mg/m2 on day 1, methylprednisolone 1000 mg/body for 3 days (from day 3 to day 5), ifosfamide 1000 mg/m2 for 5 days (from day 3 to day 7), methotrexate 30 mg/m2 on day 5 and day 12, etoposide 80 mg/m2 for 3 days (from day 3 to day 5), and carboplatin 300 mg/m2 on day 3 every 21 days. Patients aged 70 years or older were given 75% of the standard dose. The overall response rate (complete response + partial response) was 64.4%. The 2-year overall survival rate was 55.3%. The 2-year progression free survival rate was 34.7%. The 2-year overall survival rate was 61.5% for the relapse patients, and 15.6% for the refractory patients (p < 0.0001). One patient died because of sepsis related to the treatment regimen. Non-hematological adverse effects were mild and tolerable. The R-P-IMVP-16/CBDCA regimen displayed a significant activity in relapsed DLBCL, with acceptable toxicity, and should be considered a candidate for salvage chemotherapy. Copyright © 2016 John Wiley & Sons, Ltd.

Web of Science ® 被引用回数 : 3

リンク情報
DOI
https://doi.org/10.1002/hon.2285
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/26999778
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000410668700003&DestApp=WOS_CPL

エクスポート
BibTeX RIS